Brazilian Anti-Cancer Plant Yields Three New Molecules and a Structural Surprise

Deep in the savannas and cerrado of Mato Grosso do Sul, Brazil, a modest member of the coffee family has been quietly earning a reputation among traditional healers. Galianthe thalictroides, a slender herb whose roots are brewed into a decoction used for the treatment and prevention of cancer, has now given up its most complete chemical inventory to date. An international team spanning Brazilian and Swiss laboratories has isolated and characterized twenty-six compounds from its roots, discovering three molecules entirely new to science, correcting the structures of two previously reported alkaloids, and demonstrating that some of these compounds can kill triple-negative breast cancer cells with remarkable potency. The study, published in Frontiers in Natural Products, also uncovered something subtler and arguably more exciting: evidence that the plant’s anticancer reputation may rest on a coordinated cocktail of molecules rather than a single magic bullet.

The investigation began with a pragmatic problem. Earlier work had shown that the chloroform fraction of G. thalictroides roots was strongly cytotoxic against cancer cell lines, and four active compounds had already been isolated, including two beta-carboline alkaloids and two cyclopeptides. But several minor metabolites visible in chromatographic profiles could not be captured in sufficient quantity for full structural elucidation. To close these gaps, the researchers re-extracted four kilograms of dried roots with ethanol, partitioned the resulting extract into hexane, chloroform, and ethyl acetate fractions, and prepared a traditional water decoction in parallel, mirroring exactly how local practitioners steep half a teaspoon of dried root in boiling water and drink it twice a day.

Before any purification began, the team mapped the plant’s entire metabolome using ultra-high-performance liquid chromatography coupled with high-resolution tandem mass spectrometry. The resulting data were assembled into a molecular network, a computational map in which each node represents a detected compound and edges connect molecules with similar fragmentation patterns. The network contained 2,066 nodes linked by 3,075 edges, and through in silico database searching combined with a taxonomically informed scoring filter, the team tentatively annotated 284 compounds, refining thirteen of them to metabolites previously reported in the Rubiaceae family. Distinct clusters emerged corresponding to indole alkaloids characteristic of the plant family and to the cyclopeptides already known from this species.

Armed with this map, the researchers then chased the actual molecules. Medium-pressure liquid chromatography with ultraviolet detection generated eighty-two fractions, many of which were further purified by semi-preparative HPLC, ultimately yielding twenty-six fully characterized compounds. The haul included phenolic glycosides, iridoids, coumarins, lignans, anthraquinones, and two important families of nitrogen-containing metabolites: Rubiaceae-type cyclopeptides of the bouvardin series and beta-carboline alkaloids. Three of the isolated compounds proved to be previously unknown natural products, and one anthraquinone, 1-methoxy-2,7-dihydroxyanthraquinone, was reported as a natural-source isolate for the first time.

The new cyclopeptides were the first major prize. Compound 18, named 5-beta-hydroxy-RA-XII, turned out to be a bouvardin-type cyclic hexapeptide bearing an appended glucose unit attached to the tyrosine-6 residue, a feature confirmed by nuclear magnetic resonance correlations from the sugar’s anomeric proton to the aromatic carbon of the tyrosine ring and by high-resolution mass spectrometry. Compound 19, dubbed 5-beta-hydroxy-RA-I, carries an additional oxygen relative to bouvardin: careful inspection of its spectra revealed that a methyl doublet belonging to the alanine-2 residue had vanished, replaced by an oxymethylene signal, indicating that an alanine had been converted to a serine. Both nomenclatures follow the RA-series convention established decades ago for related antitumor hexapeptides from Rubia species.

The most consequential chemical revision involved the beta-carboline alkaloids 24 and 25, which had been described in earlier studies of the same species. The original assignments posited two independent tertiary alcohols in the aliphatic side chain and treated key mass spectrometric ions as water-loss adducts. The new analysis flipped that interpretation. Instead, the team proposed that the two tertiary alcohols cyclize to form an internal ether, creating an extra five-membered ring, so that the observed ions correspond directly to protonated molecules. Carbon-13 chemical shift comparisons with structurally related ether-bridged compounds in the literature supported this reading, and the consistency of the proposed structures with all one- and two-dimensional NMR data was verified using the CT web application, which performs complete quantum mechanical spectral analysis, iteratively optimizing chemical shifts and coupling constants against calculated proton spectra.

Establishing the three-dimensional architecture demanded additional computational muscle. Relative configurations were locked down through nuclear Overhauser effect correlations, while absolute configurations were assigned by comparing experimental electronic circular dichroism spectra with spectra calculated for both candidate stereoisomers using time-dependent density functional theory. For the revised alkaloid 24, the experimental trace matched the 14R,15R,18S isomer. For the genuinely new alkaloid 23, which features an intramolecular ether bridge and a hydroxylated methine in a compact tetracyclic framework, the calculations pointed unambiguously to the 14S,15S,18R,19R configuration. Every structural claim in the paper therefore rests on converging lines of spectroscopic and computational evidence rather than a single technique.

With pure compounds in hand, the biological evaluation delivered striking results. Testing against BT-20 triple-negative breast cancer cells, an aggressive subtype lacking the three most common therapeutic targets, the bouvardin family dominated the potency rankings. Bouvardin itself and 6-O-methylbouvardin inhibited cell survival with IC50 values of roughly 0.25 micromolar, while 5-beta-hydroxy-RA-III followed at 2.7 micromolar. Structure-activity patterns emerged clearly: adding a hydroxyl group at the alanine-2 position reduced potency several-fold, and the bulky, highly polar glucose of compound 18 attenuated activity tenfold, plausibly by limiting cellular uptake. Anthraquinones showed moderate activity between 23 and 110 micromolar, and the beta-carbolines ranged from 65 to 193 micromolar, weaker but still biologically meaningful. Mechanistically, bouvardins are known inhibitors of protein biosynthesis, while anthraquinones can generate reactive oxygen species and form the scaffold of several approved anticancer drugs.

The beta-carbolines told a more intriguing mechanistic story. Because this scaffold had previously been shown to suppress Wnt signaling, a central oncogenic pathway implicated in tumor progression, therapy resistance, cancer stem cell maintenance, and epithelial-mesenchymal transition, the researchers ran a TopFlash reporter assay measuring Wnt3a-driven transcription in the same BT-20 cells. Compound 24 emerged as a selective Wnt pathway inhibitor with an IC50 near 40 micromolar, while its close analog 25, lacking the C-19 hydroxyl group, showed no specific Wnt inhibition at all. Compound 23 was entirely inactive, likely because its indole nitrogen is sequestered in an intramolecular cyclization and cannot engage biological targets. Both active and inactive derivatives were ten to twenty times less potent than the best Wnt-targeting beta-carbolines reported previously, so the authors are candid that these particular molecules are not optimal scaffolds, but the sharp activity difference between 24 and 25 provides a valuable structural clue about which molecular features matter for pathway inhibition.

Perhaps the most provocative conclusion concerns the plant as a whole. The cytotoxic bouvardins and the Wnt-selective beta-carboline coexist in the same chloroform fraction, and the authors argue that this combination may function as a multi-component anticancer system, with Wnt inhibition potentially sensitizing cancer cells to cytotoxic stress and simultaneous effects on tumor progression, recurrence, and apoptosis. Notably, the molecular network revealed that the cyclopeptides and beta-carbolines appear absent or only trace in the traditional water decoction, raising questions about which constituents actually reach patients drinking the remedy. The authors frame their findings as a foundation for pharmacological investigation, in vivo studies, and ultimately drug development, and the discovery of three new molecules, the correction of two flawed structures, and the demonstration of pathway-specific activity together make G. thalictroides one of the more compelling underexplored sources of anticancer natural products to emerge from Brazilian ethnobotany in recent years.

Subject of Research: Phytochemistry and anticancer bioactivity of Galianthe thalictroides metabolites

Article Title: Comprehensive phytochemical study of Galianthe thalictroides: isolation of three new compounds, structural revision of β-carbolines, and evaluation of cytotoxic and anti-wnt activities

Article References: Comprehensive phytochemical study of Galianthe thalictroides: isolation of three new compounds, structural revision of β-carbolines, and evaluation of cytotoxic and anti-wnt activities. (n.d.). https://doi.org/10.3389/fntpr.2026.1840056

Image Credits: AI Generated

DOI: 10.3389/fntpr.2026.1840056

Keywords: Galianthe thalictroides, natural products, cyclopeptides, beta-carboline alkaloids, Wnt signaling, cytotoxicity, triple-negative breast cancer, molecular networking, NMR, electronic circular dichroism, bouvardin, ethnopharmacology